Hemogenyx Pharmaceuticals Plc (LSE: HEMO)
Health Care · Biotechnology · GB
£6.58
-10.48% today · -34.2% 1Y
Hemogenyx Pharmaceuticals Plc (LSE: HEMO) operates in the Biotechnology industry within the Health Care sector. The company is valued at $59.69M and employs 16 people.
Over the last twelve months the share price has lost 34.2%, trading between 3.56 and 12.20.
Tweenvest scores Hemogenyx Pharmaceuticals Plc across four factors: quality 33/100, value 66/100. Its strongest factor is value.
HEMO price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $59.69M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -1.92
- Dividend yield
- —
- Beta (5Y)
- 1.52
- 52-week high
- £12.20
- 52-week low
- £3.56
- Avg volume (3M)
- —
- Shares outstanding
- 6.80M
- Employees
- 16
- Next earnings
- —
About Hemogenyx Pharmaceuticals Plc
Hemogenyx Pharmaceuticals Plc is a preclinical biotechnology company dedicated to the discovery, advancement, and commercialization of innovative therapies for various blood diseases. The firm's pipeline is heavily focused on creating novel solutions for the bone marrow and hematopoietic stem cell (BM/HSC) transplant sector. Key developments include a CDX bi-specific antibody, engineered to target challenging conditions such as relapsed/refractory acute myeloid leukaemia (R/R AML), specific forms of acute lymphoblastic leukaemia, and myelodysplastic syndrome, aiming to replace traditional chemotherapy or radiation for transplant conditioning. Also under development is HEMO-CAR-T therapy, which utilizes chimeric antigen receptor T-cells to effectively identify and destroy human acute myeloid leukaemia cells in laboratory and in vivo settings. Additionally, the company is advancing Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapeutic specifically for BM/HSC transplant procedures. Founded in 2012, Hemogenyx Pharmaceuticals is headquartered in London, United Kingdom.
- ISIN
- GB00BQVXM815
- Founded
- 2013
- Listed since
- Nov 9, 2015
- Exchange
- London Stock Exchange
- Currency
- GBP
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| EyeGene Inc.KOSDAQ: A185490 | $63.26M | ₩1,951.00 | +4.33% |
| Nuo Therapeutics, Inc.OTCPK: AURX | $62.96M | $1.30 | +4.00% |
| OS Therapies IncorporatedNYSEAM: OSTX | $60.89M | $1.32 | -18.52% |
| Pharos iBio Co., Ltd.KOSDAQ: A388870 | $60.30M | ₩6,210.00 | -3.12% |
| Gossamer Bio, Inc.NasdaqGS: GOSS | $58.75M | $9.61 | +1.53% |
| Zelluna ASAOB: ZLNA | $58.51M | Nkr18.50 | -5.85% |
| Adaptin Bio, Inc.OTCPK: APTN | $57.89M | $— | — |
| Biosino Bio-Technology and Science IncorporationSEHK: 8247 | $57.71M | HK$3.13 | -0.32% |
Figures last refreshed Oct 18, 2026.